These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29745930)

  • 21. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study.
    Brausi M; Campo B; Pizzocaro G; Rigatti P; Parma A; Mazza G; Vicini A; Stephen RL
    Urology; 1998 Mar; 51(3):506-9. PubMed ID: 9510365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical electro-osmotic administration of mitomycin C.
    Di Stasi SM; Verri C; Celestino F; De Carlo F; Pagliarulo V
    Urologia; 2016 Oct; 83(Suppl 2):18-23. PubMed ID: 27716887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitomycin C from birth to adulthood.
    Serretta V; Scalici Gesolfo C; Alonge V; Di Maida F; Caruana G
    Urologia; 2016 Oct; 83(Suppl 2):2-6. PubMed ID: 27716885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
    Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
    BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intravesical Electromotive Drug Administration®(EMDA)with Mitomycin-C for non-muscle invasive bladder cancer].
    Di Stasi SM; Dutto L; Verri C
    Urologia; 2008; 75(4):214-20. PubMed ID: 21086335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
    Weiss BE; Pietzak EJ; Wein AJ; Malkowicz SB; Guzzo TJ
    Can J Urol; 2015 Aug; 22(4):7876-81. PubMed ID: 26267025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
    Järvinen R; Kaasinen E; Rintala E; Group TF
    Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review.
    Carando R; Pradere B; Afferi L; Marra G; Aziz A; Roghmann F; Krajewski W; Di Bona C; Alvarez-Maestro M; Pagliarulo V; Xylinas E; Moschini M
    Prog Urol; 2020 May; 30(6):322-331. PubMed ID: 32279953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?
    Badalato GM; Hruby G; Razmjoo M; McKiernan JM
    Can J Urol; 2011 Oct; 18(5):5890-5. PubMed ID: 22018151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro biocompatibility between mitomycin-C (MMC) and bacillus Calmette-Guerin (BCG).
    Mitsogiannis IC; Psaroudaki Z; Perrea D; Paniara O; Melekos MD; Zervas A; Mitropoulos D
    Anticancer Res; 2006; 26(6B):4569-73. PubMed ID: 17201179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitomycin C: new strategies to improve efficacy of a well-known therapy.
    Ragonese M; Racioppi M; Bassi PF; Di Gianfrancesco L; Lenci N; Filianoti A; Recupero SM
    Urologia; 2016 Oct; 83(Suppl 2):24-28. PubMed ID: 27647081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Liberati E; Dutto L; Verri C
    Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.].
    Chantada-Abal V; Chantada-Tirado C; Lamas-Díaz L; Caramés-Masana F; Villegas-Piguave AD; Villar-Vázquez N
    Arch Esp Urol; 2018 May; 71(4):453-457. PubMed ID: 29745935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitomycin C for the treatment of bladder cancer.
    Volpe A; Racioppi M; D'Agostino D; Cappa E; Filianoti A; Bassi PF
    Minerva Urol Nefrol; 2010 Jun; 62(2):133-44. PubMed ID: 20562793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemohyperthermia: Our experience after 10 years.
    Sousa Escandón A; León Mata J; Sousa González D; Alvarez Casal M; Rodríguez S; Piñeiro Vazquez S
    Arch Esp Urol; 2018 May; 71(4):438-446. PubMed ID: 29745933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.
    Malmström PU; Wijkström H; Lundholm C; Wester K; Busch C; Norlén BJ
    J Urol; 1999 Apr; 161(4):1124-7. PubMed ID: 10081852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
    Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
    Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.